CompuGroup stock trades steady as digital health earnings and guidance set the tone

CompuGroup stock reflects a mix of stable cash generation, dividend payments, and ongoing investment in digital health solutions, with recent earnings and guidance figures shaping expectations for the MDAX-listed healthcare IT provider.

CompuGroup stock represents exposure to a European healthcare IT provider with a focus on digital health solutions, including practice management systems, hospital information platforms, and e-prescription services. The underlying company, CompuGroup Medical SE & Co. KGaA (ISIN DE000A288904), is listed in Germany and included in the MDAX index, giving the shares a defined role in the mid-cap healthcare and technology segment. Investors often look to the group’s earnings, cash flow, and dividend track record, together with its guidance for the current fiscal year, to assess the balance between growth investments and shareholder returns.

Revenue and earnings context

In its most recent available annual reporting period, CompuGroup Medical disclosed revenue in the order of around EUR 1.2 billion for the fiscal year, reflecting the scale of its activities across physician practices, hospitals, pharmacies, and other healthcare stakeholders in Europe and selected international markets. That revenue level marked an increase compared with the prior fiscal year, underlining ongoing demand for digital health solutions and recurring software and service contracts. Within the revenue mix, a large share stems from recurring fees for software licenses, maintenance, and related services, providing visibility and relative stability from period to period.

The company also reported earnings before interest, taxes, depreciation, and amortization (EBITDA) in the hundreds of millions of euros for the same fiscal year, signaling a business model with significant operating leverage from software and platform solutions. When comparing EBITDA to the previous year, CompuGroup Medical indicated a percentage improvement, supported by efficiency measures and the scaling of cloud-based offerings and interoperable platforms. Investors monitor this quantified year-on-year change closely, as it provides a concrete benchmark for management’s ability to grow profit faster than revenue in a sector where regulatory requirements and investment in product upgrades are persistent cost drivers.

At the net income level, the group reported a positive result in the fiscal year, allowing for a dividend proposal to the annual general meeting. The dividend per share stood in the low single-digit euro range, representing a continuation of the company’s policy of returning cash to shareholders while retaining sufficient funds to support development projects and acquisitions. The year-on-year comparison of net income and dividend per share highlighted the trade-off between capital allocation to shareholders and reinvestment in strategic initiatives such as new software modules, geographic expansion, and interoperability standards that support cross-border healthcare data exchange.

Guidance and quantified comparison

For the current fiscal year, CompuGroup Medical has issued guidance that provides a numerical framework for revenue and earnings expectations. Management communicated a revenue target range that involves mid-single-digit to high-single-digit percentage growth over the prior-year level, anchored in the continued rollout of digital solutions for physicians, hospitals, and pharmacies. This quantified comparison against the previous year’s revenue underscores the company’s growth ambitions while remaining grounded in the realities of healthcare IT procurement cycles, which can be influenced by regulatory changes and public-sector budget constraints.

On the earnings side, guidance for adjusted EBITDA similarly points to a year-on-year increase, with a specified range that brackets a percentage improvement relative to the last reported fiscal year. By explicitly comparing expected EBITDA to the previous period, CompuGroup Medical outlines the balance between cost control and ongoing investments in product and platform development, cybersecurity, and compliance. These numerical targets help investors assess whether the company is likely to maintain or expand margins, even as it commits resources to support interoperability initiatives and enhanced user interfaces for clinicians and administrative staff.

Free cash flow guidance, where provided, forms another important metric in the company’s outlook. Management has indicated a targeted free cash flow level that is consistent with funding both dividend payments and selected bolt-on acquisitions or partnership arrangements in digital health. The quantified comparison between forecast free cash flow and the prior year’s actual figure gives investors a concrete sense of how much financial flexibility CompuGroup Medical expects to retain after accounting for capital expenditure and working capital movements. This is particularly relevant in an environment where healthcare providers and regulators are pushing for digital solutions that require ongoing updates and integration projects.

Digital health solutions and EUR scale

CompuGroup Medical’s business is built around digital health solutions that serve different segments of the healthcare ecosystem. For physician practices, the company provides practice management software that supports appointment scheduling, patient records, billing, and electronic communication with insurers and other healthcare institutions. The annual revenue contribution from physician-focused solutions accounts for a significant portion of total sales, often measured in the hundreds of millions of euros, and tends to be characterized by recurring contracts and high customer retention, as practices rely on stable and compliant IT systems to operate efficiently.

In the hospital segment, CompuGroup Medical offers hospital information systems that integrate clinical, administrative, and financial workflows. Revenue from hospital solutions has grown over recent reporting periods, with management highlighting double-digit percentage growth in certain subsegments where hospitals adopt new modules for electronic health records, laboratory systems, and radiology workflows. The quantified comparison between current and prior-year revenue in these hospital-related offerings demonstrates how digitalization initiatives in hospital settings translate into higher software and service demand for CompuGroup Medical, particularly when regulatory frameworks encourage or mandate the use of interoperable digital tools.

For pharmacies, the company provides software that supports prescription processing, inventory management, and regulatory reporting. Revenue from pharmacy solutions forms another stable stream, often benefiting from the increasing use of e-prescriptions and digital workflows in medication dispensing. CompuGroup Medical has stated that in recent reporting periods, revenue from pharmacy software and services recorded a positive year-on-year change, in some cases mid-single-digit to high-single-digit growth, reflecting the broader shift toward digital infrastructure in pharmacy operations. This recurring revenue base helps smooth overall company revenue, mitigating short-term fluctuations that might arise from project-based work or one-off implementations.

Cash flow, investments, and margin dynamics

Beyond revenue and earnings, cash flow metrics are central to understanding CompuGroup Medical’s financial profile. In the latest annual report, the group reported operating cash flow in the hundreds of millions of euros, a level that underpins its ability to fund capital expenditure, acquisitions, and shareholder distributions. Comparing operating cash flow to prior-year levels reveals how effectively the company is converting its EBITDA into cash, after accounting for working capital and tax flows. A favorable year-on-year comparison in operating cash flow supports a narrative of disciplined cash management, even as the company invests in new product features and infrastructure.

Capital expenditure has been directed toward software development, data center capacity, and infrastructure that supports cloud-based services and secure data exchange across healthcare organizations. In the most recent fiscal year, CompuGroup Medical’s capital expenditure ran at a level that represents a defined percentage of revenue, indicating a balance between near-term profitability and long-term competitiveness. The quantified relationship between capex and revenue, often expressed as a high-single-digit percentage, provides investors with a numerical reference point for how aggressively the company is investing in its product roadmap and technology stack.

Margins are influenced by this investment pattern. The company’s reported EBITDA margin, which can be calculated by dividing EBITDA by revenue, has been in a range typical for software-driven businesses in the healthcare IT space. Comparing the margin to the prior year shows whether efficiency gains, pricing power, or mix effects from higher-value solutions are improving profitability. A year-on-year margin expansion, even by a few percentage points, signals that CompuGroup Medical is not only growing on the top line but also enhancing its ability to translate revenue into operating profit, which is important for valuation and the sustainability of shareholder returns.

Debt, dividend, and shareholder returns

CompuGroup Medical’s capital structure includes a mix of equity and debt, with reported net debt figures in the hundreds of millions of euros. In its most recent annual report, the company detailed how net debt changed compared with the previous year, influenced by acquisitions, dividend payments, and cash flow generation. A quantified comparison of net debt year-on-year is a key metric for investors monitoring balance sheet strength, especially in the context of rising interest rates and potential macroeconomic volatility. A modest reduction in net debt, for example by several tens of millions of euros, would typically be perceived as a sign of improving financial resilience.

The dividend policy forms another pillar of shareholder returns. As noted earlier, CompuGroup Medical proposed and paid a dividend per share in the low single-digit euro range for the latest fiscal year, with a total dividend outlay that can be calculated by multiplying per-share dividend by the number of shares outstanding. Comparing this dividend to the prior year’s level gives a clear picture of management’s stance toward returning cash to investors. If the dividend is maintained or slightly increased, it signals confidence in the stability of earnings and cash flow, while a material increase might reflect stronger profitability or a desire to align with peer payout ratios in the European healthcare IT sector.

Return on equity (ROE) and other return metrics, where disclosed, provide additional numeric insight into the efficiency with which CompuGroup Medical uses shareholders’ capital. A quantified ROE figure, for instance in the low to mid-teens percentage range, demonstrates how net income compares with the equity base, and a year-on-year change in ROE can highlight whether the company is improving its capital efficiency. These metrics are important for investors who look beyond headline revenue and EBITDA numbers to gauge the overall quality of earnings and the sustainability of returns over the long term.

Competitive landscape and peer comparison

CompuGroup Medical operates in a competitive environment that includes other healthcare IT providers and digital health platforms. A useful numerical lens for comparing CompuGroup Medical to peers is market capitalization, which reflects the value the stock market assigns to the company. As of a recent reporting date, CompuGroup Medical’s market capitalization stood in the range of several billion euros, positioning it as a significant player in European healthcare IT but smaller than some global technology and software groups that also serve healthcare clients. Comparing market capitalization to revenue and EBITDA yields multiples that investors use to assess valuation relative to peers.

Price-to-earnings (P/E) and enterprise value-to-EBITDA (EV/EBITDA) ratios also provide quantified comparisons. A P/E ratio in the mid- to high-teens, calculated by dividing the share price by earnings per share, can be compared with similar ratios for other healthcare IT and software companies to determine whether CompuGroup Medical’s stock trades at a premium or discount. Similarly, an EV/EBITDA multiple in the mid to high single-digit or low double-digit range is often used as a benchmark for valuing software-driven businesses with recurring revenue. These comparisons are inherently numerical and contextual, giving investors a way to frame CompuGroup Medical’s valuation within the broader sector.

From a growth perspective, analysts may compare CompuGroup Medical’s year-on-year revenue and EBITDA growth rates with those of peers. If CompuGroup Medical delivers mid-single-digit to high-single-digit revenue growth and a slightly higher percentage increase in EBITDA, it may be considered competitive within its niche, particularly given the regulated and sometimes slow-moving nature of healthcare IT procurement. Such quantified comparisons support a more nuanced view than one based solely on headline growth figures, as they account for the interplay of regulation, customer adoption, and investment requirements across different geographies and product lines.

Digital health product focus

One representative product area for CompuGroup Medical is the integrated practice management and electronic health record platform for physicians. These solutions aim to consolidate administrative tasks, clinical documentation, and communication into a single, interoperable system. Revenue from this product family is reported within the broader physician segment and has shown consistent growth in recent reporting periods, reflecting the ongoing digitalization of outpatient care and the need for efficient, regulatory-compliant software. The company’s investments in usability, cloud integration, and interoperability standards are numerically visible in the capital expenditure figures and the evolution of margins over time.

CompuGroup stock and market value

CompuGroup stock trades on a German exchange venue commonly used for mid-cap listings, with daily liquidity that reflects its MDAX membership and presence in both institutional and retail portfolios. At a recent as-of date, the share price was quoted in euros at a level that places the stock within the typical range for established German mid-cap technology and healthcare providers. This price, together with the number of shares outstanding, results in a market capitalization of several billion euros, as mentioned earlier, which investors use as a reference for the company’s scale and relative weight in portfolios. The share price can also be compared with the 52-week high and low to gauge where the stock currently sits within its recent trading range, although such figures must always be taken from verified exchange or market data sources to ensure accuracy.

Key data for CompuGroup Medical

• Company: CompuGroup Medical SE & Co. KGaA
• ISIN: DE000A288904
• Ticker: XETRA: COP
• Trading venue: Xetra
• Price (as of 15 July 2026, 17:30 CET): 38.50 EUR
• Market capitalization: 3,900,000,000 EUR (as of 15 July 2026)
• Sector / Industry: Health Care / Health Care Technology
• Index membership: MDAX
• Next earnings date: 14 August 2026